Skip to main content

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

"TCR2 continued to execute on its streamlined corporate priorities in the last quarter and stands poised to deliver multiple clinical catalysts over the next 12 months on our two core assets, gavo-cel and TC-510," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "In the Phase 1 trial for gavo-cel, we observed promising activity in ovarian cancer, leading us to place greater and earlier emphasis on this indication. We also established a baseline clinical profile which we believe positions gavo-cel as a first- and best-in-class anti-mesothelin monotherapy which we aim to further enhance with the addition of checkpoint inhibitors and redosing strategies in the Phase 2 portion of the trial. In addition, we have begun treating patients with our second product candidate, TC-510, a TRuC-T cell enhanced with a PD-1:CD28 chimeric switch receptor. These near-term focused activities will allow us to further maximize the number of cancer patients with access to our investigational therapies."

Recent Developments


  • TCR2 announced positive topline results from the complete Phase 1 dose escalation portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors. Twenty-eight of the 30 patients evaluable for efficacy experienced regression of their target lesions, including eight patients who achieved a partial response (PR) by target lesion assessment, six of whom met criteria for a PR according to RECIST 1.1 criteria. Following identification of a dose-limiting toxicity (DLT) in September 2021, the study proceeded to a dose de-escalation portion and subsequently declared dose level 3 (1x108 cells/m2 following lymphodepletion) the recommended Phase 2 dose (RP2D).
  • Enrollment and treatment in the Phase 2 expansion portion of the gavo-cel Phase 1/2 clinical trial is ongoing.
  • TCR2 presented new preclinical data at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting demonstrating gavo-cel maintained effector function to clear tumors and was not impaired, blocked or disrupted by functional suppression from supraphysiological levels of soluble mesothelin-related peptides.


• Enrollment and treatment in the Phase 1 dose escalation portion of the TC-510 Phase 1/2 clinical trial is ongoing.

Financial Highlights

  • Cash Position: TCR2 ended the third quarter of 2022 with $176.0 million in cash, cash equivalents, and investments compared to $265.6 million as of December 31, 2021. Net cash used in operations was $25.8 million for the third quarter of 2022 compared to $19.4 million for the third quarter of 2021. TCR2 continues to project net cash use of $115-125 million for 2022. We expect cash on hand to support operations into 2024.
  • R&D Expenses: Research and development expenses were $24.8 million for the third quarter of 2022 compared to $20.3 million for the third quarter of 2021. The increase in R&D expenses was primarily due to an increase in clinical trial expenses associated with patient treatment and product manufacturing.
  • G&A Expenses: General and administrative expenses were $6.3 million for the third quarter of 2022 compared to $6.0 million for the third quarter of 2021. The slight increase in general and administrative expenses was due to an increase supporting corporate activities.
  • Net Loss: Net loss was $30.6 million for the third quarter of 2022 compared to $26.2 million for the third quarter of 2021.

Upcoming Events

TCR2 Therapeutics management is scheduled to participate at the following upcoming conferences.

  • Jefferies London Healthcare Conference: Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress on Tuesday, November 15, 2022 at 5:35pm GMT (12:35pm ET)

About TCR2 Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit

About gavo-cel

Gavo-cel is a mesothelin-targeted TRuC-T cell. The ongoing gavo-cel Phase 1/2 clinical trial is evaluating the safety and efficacy of gavo-cel in patients with mesothelin-expressing malignant pleural/peritoneal mesothelioma (MPM), ovarian cancer, non-small cell lung cancer (NSCLC) and cholangiocarcinoma.

About TC-510

TC-510 is a mesothelin-targeted TRuC-T cell that co-expresses a PD-1:CD28 chimeric switch receptor to provide a local costimulatory signal by engaging with PD-L1 expressed in the hostile tumor microenvironment and converting the negative inhibitory signal into a positive costimulatory signal.

Forward-looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. The use of words such as "will," "expects," "plans," "believes," "predicts," "projects," "aims," "allows," “promising,” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding TCR2’s plans, strategies, timelines, and expectations for its gavo-cel and TC-510 clinical trials, statements regarding IND-enabling studies on TC-520, express or implied statements regarding the therapeutic potential of gavo-cel, TC-510 and TCR2’s other product candidates in treating cancer patients and improving access to investigational therapies for cancer, and statements regarding expected cash use in 2022 and cash runway into 2024.

The expressed or implied forward-looking statements included in this press release are only current expectations, beliefs, and predictions and are subject to a number of risks, uncertainties, assumptions and important factors, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure manufacturing capacity; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties, assumptions and important factors, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those expressed or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667

(amounts in thousands, except share data)

 September 30,
  December 31,
Current assets     
Cash and cash equivalents$54,006  $222,564 
Investments 121,980   43,029 
Prepaid expenses and other current assets 8,093   10,534 
Total current assets 184,079   276,127 
Property and equipment, net 29,083   17,075 
Right-of-use assets, operating leases 57,704   28,283 
Restricted cash 1,152   1,156 
Other assets, non-current 909   730 
Total assets$272,927  $323,371 
Liabilities and stockholders’ equity     
Accounts payable$2,963  $2,144 
Accrued expenses and other current liabilities 13,185   13,094 
Operating lease liabilities 20,545   3,367 
Total current liabilities 36,693   18,605 
Operating lease liabilities, non-current 37,684   22,996 
Other liabilities -   293 
Total liabilities 74,377   41,894 
Stockholders’ equity     
Common stock, $0.0001 par value; 150,000,000 shares authorized; 38,657,061 and 38,496,484 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. 4   4 
Additional paid-in capital 639,981   631,008 
Accumulated other comprehensive income (loss) (596)  (13)
Accumulated deficit (440,839)  (349,522)
Total stockholders’ equity 198,550   281,477 
Total liabilities and stockholders’ equity$272,927  $323,371 

(amounts in thousands, except share and per share data)

 Three Months Ended
September 30,
  Nine Months Ended
September 30,
 2022  2021  2022  2021 
Operating expenses           
Research and development$24,791  $20,277  $73,441  $54,828 
General and administrative 6,312   5,963   18,636   17,297 
Total operating expenses 31,103   26,240   92,077   72,125 
Loss from operations (31,103)  (26,240)  (92,077)  (72,125)
Interest income, net 510   38   925   186 
Loss before income tax expense (30,593)  (26,202)  (91,152)  (71,939)
Income tax expense 1   42   165   129 
Net loss$(30,594) $(26,244) $(91,317) $(72,068)
Per share information           
Net loss per share of common stock, basic and diluted$(0.79) $(0.69) $(2.37) $(1.91)
Weighted average shares outstanding, basic and diluted 38,620,751   38,197,929   38,567,331   37,816,345 

(amounts in thousands)

 Nine Months Ended September 30, 
 2022  2021 
Operating activities     
Net loss$(91,317) $(72,068)
Adjustments to reconcile net loss to cash used in operating activities:     
Depreciation and amortization 2,300   1,976 
Stock-based compensation expense 8,717   9,525 
(Accretion) / Amortization on investments (403)  626 
Deferred tax liabilities (293)  105 
Changes in operating assets and liabilities:     
Prepaid expenses and other current assets 2,618   (41)
Operating leases, net 2,445   (2,811)
Accounts payable (637)  2,066 
Accrued expenses and other liabilities 66   2,299 
Cash used in operating activities (76,504)  (58,323)
Investing activities     
Purchases of equipment (12,681)  (4,352)
Software development costs (330)  (308)
Purchases of investments (215,619)  (40,732)
Proceeds from sale or maturity of investments 136,488   140,622 
Cash provided by (used in) investing activities (92,142)  95,230 
Financing activities     
Proceeds from public offering of common stock, net of issuance costs -   131,330 
Proceeds from the exercise of stock options 256   1,013 
Payment of deferred offering costs (172)  (336)
Cash provided by financing activities 84   132,007 
Net change in cash, cash equivalents, and restricted cash (168,562)  168,914 
Cash, cash equivalents, and restricted cash at beginning of year 223,720   94,738 
Cash, cash equivalents, and restricted cash at end of period$55,158  $263,652 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.